A novel approach to cardiovascular disturbances in patients with schizophrenia spectrum disorders treated with long-acting injectable medication

References

• AlbertiKGZimmetPShawJMetabolic syndrome – a new world-wide definition. A consensus statement from the international diabetes federationDiabet Med200623546948016681555
   PubMed Web of Science ®Google Scholar
• AurigemmaGPSilverKHPriestMAGaaschWHGeometric changes allow normal ejection fraction despite depressed myocardial shortening in hypertensive left ventricular hypertrophyJ Am Coll Cardiol19952611952027797752
   PubMed Web of Science ®Google Scholar
• CarrilloJAHerráizAGRamosSIGervasiniGVizcaínoSBenítezJRole of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapineJ Clin Psychopharmacol200323211912712640212
   PubMed Web of Science ®Google Scholar
• CitromeLCollinsJMNordstromBLIncidence of cardiovascular outcomes and diabetes mellitus among users of second-generation antipsychoticsJ Clin Psychiatry201374121199120624434088
   PubMed Web of Science ®Google Scholar
• CoulterDMBateAMeyboomRHLindquistMEdwardsIRAnti-psychotic drugs and heart muscle disorder in international pharmacovigilance: data mining studyBMJ200132272961207120911358771
   PubMed Web of Science ®Google Scholar
• DavidsonSJuddFJolleyDHockingBThompsonSHylandBCardiovascular risk factors for people with mental illnessAust N Z J Psychiatry200135219620211284901
   PubMed Web of Science ®Google Scholar
• DeheleanLAndorMRomoşanAMTomescuMCPharmacological and disorder associated cardiovascular changes in patients with psychosis. A comparison between olanzapine and risperidoneFarmacia2018661129134
   Web of Science ®Google Scholar
• EmulMKaleliogluTEtiology of cardiovascular disease in patients with schizophrenia: current perspectivesNeuropsychiatr Dis Treat2015112493250326491327
   PubMed Web of Science ®Google Scholar
• MontastrucGFavreliereSSommetADrugs and dilated cardiomyopathies: a case/noncase study in the French PharmacoVigilance DatabaseBr J Clin Pharmacol201069328729420233200
   PubMed Web of Science ®Google Scholar
• HeiskanenTNiskanenLLyytikäinenRSaarinenPIHintikkaJMetabolic syndrome in patients with schizophreniaJ Clin Psychiatry200364557557912755662
   PubMed Web of Science ®Google Scholar
• KimDHManeenMJStahlSMBuilding a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophreniaNeurotherapeutics200961788519110200
   PubMed Web of Science ®Google Scholar
• KishimotoTNittaMBorensteinMKaneJMCorrellCULong-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studiesJ Clin Psychiatry2013741095796524229745
   PubMed Web of Science ®Google Scholar
• LangRMBadanoLPMor-AviVRecommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular ImagingEur Heart J Cardiovasc Imaging201516323327125712077
   PubMed Web of Science ®Google Scholar
• LeeTWTsaiSJHwangJPSevere cardiovascular side effects of olanzapine in an elderly patient: case reportInt J Psychiatry Med200333439940115152790
   PubMed Web of Science ®Google Scholar
• LehmanAFSteinwachsDMTranslating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendationsSchizophr Bull19982411109502542
   PubMed Web of Science ®Google Scholar
• McevoyJPMeyerJMGoffDCPrevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES IIISchizophr Res2005801193216137860
   PubMed Web of Science ®Google Scholar
• MegensAAAwoutersFHSchotteASurvey on the pharmacodynamics of the new antipsychotic risperidonePsychopharmacology (Berl)199411419237531353
   PubMed Web of Science ®Google Scholar
• MurchSTranNLiewDPetrakisMPriorDCastleDEchocardiographic monitoring for clozapine cardiac toxicity: lessons from real-world experienceAustralas Psychiatry201321325826123439546
   PubMed Web of Science ®Google Scholar
• NasrallahHAAtypical antipsychotic-induced metabolic side effects: insights from receptor-binding profilesMolecular Psychiatry2008131273517848919
   PubMed Web of Science ®Google Scholar
• O’BrienPOyebodeFO’BrienPFemiOPsychotropic medication and the heartAdv Psychiatric Treat200396414423
   Google Scholar
• PaulusWJTschöpeCSandersonJEHow to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of CardiologyEur Heart J200728202539255017428822
   PubMed Web of Science ®Google Scholar
• RemingtonGSchizophrenia, antipsychotics, and the metabolic syndrome: is there a silver lining?Am J Psychiatry200616371132113416816213
   PubMed Web of Science ®Google Scholar
• RingenPAEnghJABirkenaesABDiesetIAndreassenOAIncreased mortality in schizophrenia due to cardiovascular disease – a non-systematic review of epidemiology, possible causes, and interventionsFront Psychiatry2014513725309466
   PubMed Web of Science ®Google Scholar
• RobinsonDSInsulin secretion and psychotropic drugsPrim Psych2006132627
   Google Scholar
• SaariKMLindemanSMViiloKMA 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort studyJ Clin Psychiatry200566555956315889940
   PubMed Web of Science ®Google Scholar
• SengeløvMJørgensenPGJensenJSGlobal longitudinal strain is a superior predictor of all-cause mortality in heart failure with reduced ejection fractionJACC Cardiovasc Imaging20158121351135926577264
   PubMed Web of Science ®Google Scholar
• SimonVvan WinkelRde HertMAtypical antipsychotics dose dependent? A literature reviewJ Clin Psych200970710411050
   Web of Science ®Google Scholar
• SutherlandGRDi SalvoGClausPD’HoogeJBijnensBStrain and strain rate imaging: a new clinical approach to quantifying regional myocardial functionJ Am Soc Echocardiogr200417778880215220909
   PubMed Web of Science ®Google Scholar
• VinereanuDLimPOFrenneauxMPFraserAGReduced myocardial velocities of left ventricular long-axis contraction identify both systolic and diastolic heart failure–a comparison with brain natriuretic peptideEur J Heart Fail20057451251915921788
   PubMed Web of Science ®Google Scholar
• WilsonPWFD’AgostinoRBLevyDBelangerAMSilbershatzHKannelWBPrediction of coronary heart disease using risk factor categoriesCirculation19989718183718479603539
   PubMed Web of Science ®Google Scholar